GLP1R and Prader-Willi syndrome: While some studies of GLP-1R agonists reported moderate improvement of hyperphagia in pediatric populations with PWS using the Hyperphagia Questionnaire, an SLR of 10 publications involving 23 patients with PWS treated with the GLP-1R agonists exenatide and liraglutide (range, 14 weeks to 4 years) identified evidence gaps and substantial heterogeneity in administration in this patient population [111–113].